Cogent Biosciences Q4/FY2021 net loss $24.9M/$72.3M; three bezuclastinib trials enrolling

Cogent Biosciences, Inc.

Cash $219.7M at Dec 31, 2021, sufficient to fund operations into 2024.
APEX Phase 2 trial in AdvSM on track for initial data in H1 2022; SUMMIT (NonAdvSM) and PEAK (GIST) actively enrolling.
Raised ~$38M via ATM in Q4 2021; shares sold at $9.25-$10.30.
R&D expenses $55.9M in FY2021 vs $25.7M in FY2020, driven by trial start-up costs and research team expansion.
Appointed Dr. Zamaneh Mikhak as SVP Head of Clinical Development; R&D Investor Event on April 8, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.